Skip to content
★ Sign in to follow
NH

Nezam H. Afdhal

Executive
F-star Therapeutics, Inc.
Total declarations
10
Company
1
▲ Purchases (9 ops.)
€119k
▼ Sales (0 ops.)
—

Latest filing published 23 Nov 2016 for F-star Therapeutics, Inc., €113k.

Insider track record

Disclosed buys
9
Disclosed sells
0
Signal history

Closed purchases

Market purchases
9

Not enough history yet: 0 closed purchases, at least 2 are needed.

Purchases by company

Nezam H. Afdhal: trading record in brief

This profile gathers the share dealings of Nezam H. Afdhal in F-star Therapeutics, Inc. Over a trading history stretching from 10 August 2016 to 23 November 2016, the count stands at 10 filings.

No open-market sale appears; the market trades are 9 purchases worth €119k. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Besides market trades, the filings include 1 share grant.

Half of the purchases are above €15k and half below. Of 9 purchases, 9 formed part of a group of insiders buying within 30 days of each other. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase.

On 23 November 2016 came the latest disclosure, a share grant for €113k in F-star Therapeutics, Inc. The last insider purchase was made public on 12 September 2016, 3,710 days ago. Typically, a trade is published a median of 1 day after it takes place. Section 16 rules allow two business days to file each Form 4. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.

Companies and markets linked to Nezam H. Afdhal

Open company profiles for insider transactions, fundamentals and analyst consensus when available.

Declarations10 total
  • ◆
    Chief Medical OfficerExecutivesF-star Therapeutics, Inc.
    119,928 USD22SEC
    13,150 shares@ US$9.1248.6% of flowCommon StockSEC:0000899243-16-034297:0
  • ▲
    Chief Medical OfficerExecutivesF-star Therapeutics, Inc.
    30,000 USD36SEC
    2,400 shares@ US$12.5011.5% of flowCommon StockSEC:0001209191-16-140920:0
    Canonical exit: 8 Dec 2016 (T+90)
  • ▲
    Chief Medical OfficerExecutivesF-star Therapeutics, Inc.
    18,445 USD36SEC
    1,550 shares@ US$11.907.1% of flowCommon StockSEC:0001209191-16-138557:0
    Canonical exit: 22 Nov 2016 (T+90)
  • ▲
    Chief Medical OfficerExecutivesF-star Therapeutics, Inc.
    1,199 USD35SEC
    100 shares@ US$11.990.5% of flowCommon StockSEC:0001209191-16-138557:1
    Canonical exit: 22 Nov 2016 (T+90)
  • ▲
    Chief Medical OfficerExecutivesF-star Therapeutics, Inc.
    4,200 USD35SEC
    350 shares@ US$12.001.6% of flowCommon StockSEC:0001209191-16-138557:2
    Canonical exit: 22 Nov 2016 (T+90)
  • ▲
    Chief Medical OfficerExecutivesF-star Therapeutics, Inc.
    20,574 USD36SEC
    1,800 shares@ US$11.437.9% of flowCommon StockSEC:0001209191-16-137269:0
    Canonical exit: 13 Nov 2016 (T+90)
  • ▲
    Chief Medical OfficerExecutivesF-star Therapeutics, Inc.
    1,149 USD35SEC
    100 shares@ US$11.490.4% of flowCommon StockSEC:0001209191-16-137269:1
    Canonical exit: 14 Nov 2016 (T+90)
  • ▲
    Chief Medical OfficerExecutivesF-star Therapeutics, Inc.
    17,296 USD30SEC
    1,600 shares@ US$10.816.7% of flowCommon StockSEC:0001209191-16-137309:0
    Canonical exit: 8 Nov 2016 (T+90)
  • ▲
    Chief Medical OfficerExecutivesF-star Therapeutics, Inc.
    11,320 USD31SEC
    1,000 shares@ US$11.324.4% of flowCommon StockSEC:0001209191-16-137309:1
    Canonical exit: 10 Nov 2016 (T+90)
  • ▲
    Chief Medical OfficerExecutivesF-star Therapeutics, Inc.
    29,458 USD32SEC
    2,600 shares@ US$11.3311.4% of flowCommon StockSEC:0001209191-16-137099:0
    Canonical exit: 10 Nov 2016 (T+90)

10 of 10 declarations